The method was a phase I clinical trial in 10 ischemic stroke patients, assessing safety through the occurrence of adverse events (AEs), serious adverse events (SAEs) and initial results through NIHSS and FIM at 3 months, 6 months and 12 months.
The method was a phase I clinical trial in 10 ischemic stroke patients, assessing safety through the occurrence of adverse events ( AEs ), serious adverse events ( SAEs ) and initial results through NIHSS and FIM at 3 months, 6 months and 12 months .